Informe del Registro Español de Pacientes con Déficit de Alfa-1-Antitripsina

Vidal, R.; Miravitlles, M.

doi:10.1016/S0300-2896(15)30919-4

Archivos de Bronconeumología

ISSN: 0300-2896

Archivos de Bronconeumologia is an international journal that publishes original studies whose content is based upon results of research initiatives dealing with several aspects of respiratory medicine including epidemiology, respiratory physiology, pathophysiology of respiratory diseases, clinical management, thoracic surgery, pediatric lung diseases, respiratory critical care, respiratory allergy and translational research. Other types of articles such as editorials, reviews, and different types of letters are also published in the journal. Additionally, the journal expresses the voice of the following scientific societies: the Spanish Respiratory Society of Pneumology and Thoracic Surgery (SEPAR; https://www.separ.es/), the Latin American Thoracic Society (ALAT; https://alatorax.org/), and the Iberian American Association of Thoracic Surgery (AIACT; http://www.aiatorax.com/).

It is a monthly journal in which all manuscripts are sent to peer-review and handled by the editor or an associate editor from the team and the final decision is made on the basis of the comments from the expert reviewers and the editors. The journal is published solely in English. All the published data is composed of novel manuscripts not previously published in any other journal and not being in consideration for publication in any other journal..

The journal is indexed at Science Citation Index Expanded, Medline/Pubmed, Embase and SCOPUS. Access to any published article is possible through the journal's web page as well as from Pubmed, ScienceDirect, and other international databases. Furthermore, the journal is also present in X, Facebook and Linkedin. Manuscripts can be submitted electronically using the following web site: https://www.editorialmanager.com/ARBR/.

Indexed in:

Current Contents/Clinical Medicine, JCR SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, SCOPUS, IBECS

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2023

8.7

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

3.5

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.464

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.482

View more metrics

Open Access Option

Journal Information

Previous article | Next article

Vol. 31. Issue 6.

Pages 299-302 (June - July 1995)

Export reference

Download PDF

Related content

Fe de errores

Arch Bronconeumol. 1995;31:36710.1016/S0300-2896(15)30904-2

This item has received

4182 Visits

Article information

Bibliography

Download PDF

Statistics

Full text is only aviable in PDF

Bibliografía

[1.]

S. Eriksson.

Alpha-1-antitrypsin deficiency: lessons learned from the bedside to the gene and back again.

Chest, 95 (1989), pp. 181-189

Medline

[2.]

J.A. Pierce.

Antitrypsin and emphysema. Perspective and prospects.

JAMA, 259 (1988), pp. 2.890-2.895

Medline

[3.]

M. Wewers.

Pathogenesis of emphysema Assessment of basic Science concepts through clinical investigation.

Chest, 95 (1989), pp. 190-195

Medline

[4.]

M. Miravitlles, R. Vidal, J. De Gracia.

Enfisema por déficit de alfa-1-antitripsina Situación actual y nuevas perspectivas para el tratamiento.

Arch Bronconeumol, 28 (1992), pp. 296-302

[5.]

R.G. Crystal, M.L. Brandy, R.C. Hubbard, D.T. Curiel, D.J. States, M.D. Holmes.

The alpha-1-antitrypsin gene and its mutations Clinical consequences and strategies for therapy.

Chest, 95 (1989), pp. 196-208

Medline

[6.]

F. Ogushi, R.C. Hubbard, G.A. Fells, A. Casolaro, D.T. Curiel, M.L. Brantly, et al.

Evaluation of the S-type of alpha-l-antitrypsin as an in vivo and in vitro inhibitor of neutrophil elastase.

Am Rev Respir Dis, 137 (1988), pp. 364-370

http://dx.doi.org/10.1164/ajrccm/137.2.364 | Medline

[7.]

J. Lieberman.

A role for intermediate, heterozygous alpha-1-antitrypsin deficiency in obstructive lung disease.

Chest, 98 (1990), pp. 522-523

Medline

[8.]

D.W. Cox, V.H. Hoeppner, H. Levison.

Protease inhibitors in patients with chronic obstructive lung disease: the alpha-1- antitrypsin heterozygote controversy.

Am Rev Respir Dis, 113 (1976), pp. 601-606

http://dx.doi.org/10.1164/arrd.1976.113.5.601 | Medline

[9.]

R.G. Crystal.

Alpha-1-antitrypsin deficiency.

Update: pulmonary diseases and disorders., pp. 19-35

[10.]

J.A. Pierce, B. Eradio, T.A. Dew.

Antitrypsin phenotypes in St Louis.

JAMA, 231 (1975), pp. 609-612

Medline

[11.]

S. DeCroo, M.I. Kamboh, R.E. Ferrell.

Population genetics of alpha-1-antitrypsin polymorphism in US whites US blacks and african blacks.

Hum Hered, 41 (1991), pp. 215-221

Medline

[12.]

E.K. Silverman, J.P. Miletich, J.A. Pierce, L.A. Sherman, S.K. Endicott, G.J. Broze, et al.

Alpha-1-antitrypsin deficiency Eligh prevalence in the St. Louis area determined by direct population screening.

Am Rev Respir Dis, 140 (1989), pp. 961-966

http://dx.doi.org/10.1164/ajrccm/140.4.961 | Medline

[13.]

American Thoracic, Society.

Guidelines for the approach to the patient with severe hereditary alpha-1-antitrypsin deficiency.

Am Rev Respir Dis, 140 (1989), pp. 1.494-1.497

http://dx.doi.org/10.1164/ajrccm/140.6.1727 | Medline

[14.]

R. Vidal, M. Miravitlles, X. De Gracia, B. Gallego, F. Morell.

Tratamiento sustitutivo del enfisema por déficit de alfa-1-antitripsina.

Med Clin, 96 (1991), pp. 180-182

[15.]

N. Seersholm, A. Kok-Jensen, A. Dirksen.

Survival of patients with severe alpha-1-antitrypsin deficiency with special reference to non-index cases.

Thorax, 49 (1994), pp. 695-698

Medline

[16.]

N. Anthonisen.

Design of a clinical trial to test a treatment of the underlying cause of emphysema.

Ann NY Acad Sci, 624 (1991), pp. 31-34

Medline

[17.]

N. Konietzko.

Alpha-1-proteinasen-inhibitor-substitution: wann und wie?.

Pneumologie, 45 (1991), pp. 485-487

Medline

[18.]

Stoller J. Update on HHLBI alpha-1-antitrypsin registry. Conferencia. En: Alpha-1-antitrypsin: a world view in 1994. Octubre, 1994.

[19.]

Canadian Thoracic Society.

Current status of alpha-1-antitrypsin replacement therapy: recommendations for the management of patients with severe hereditary deficiency.

Can Med Assoc J, 146 (1992), pp. 841-844

[20.]

M.D. Wewers, M.A. Casolaro, S.E. Sellers, S.C. Swayze, K.M. McPhaul, J.T. Wittes, et al.

Replacement therapy for alpha-1-antitrypsin deficiency associated with emphysema.

N Engl J Med, 316 (1987), pp. 1.055-1.062

http://dx.doi.org/10.1056/NEJM198706253162604 | Medline

[21.]

G.H. Caughey.

Should alpha-1-antitrypsin-deficient patients with emphysema continue to receive alpha-1-antitrypsin after lung transplantation?.

J Heart Lung Transplant, 12 (1993), pp. 708-809

Medline

El Registro Nacional de Pacientes con Déficit de Alfa-1-Antitripsina se ha constituido gracias a la colaboración de Q.F. Bayer.

Médicos participantes en el Registro: Dres. M. Arévalo. Hospital General (Albacete). J.M. Checa, Hospital Infanta Cristina (Badajoz). E. Fité y J. Izquierdo, Hospital Germans Trias i Pujol (Badalona). B. Galdiz. Hospital de Cruces (Barakaldo). A. Torres, Hospital Clínic i Provincial (Barcelona). R. Jardi, M. Miravitlles, M. Torrella y R. Vidal, Hospital Universilari Vall d’Hebron (Barcelona). P. España, Hospital de Galdakao. R. Arias, Hospital Xeral de Galicia. M. Rubio, Hospital de Girona. F. Casas, Hospital Clínico San Cecilio (Granada). M.J. Chillón, J. Jareño, F. Villegas. Hospital del Aire (Madrid). M.T. Martínez, Hospital 12 de Octubre (Madrid). L. Maiz, Hospital Ramón y Cajal (Madrid). L. Sánchez-Agudo, Instituto de Salud Carlos III (Madrid). F.J. Domínguez, Hospital de Navarra (Pamplona). J. Such. Hospital Pare Tauli (Sabadell). P. de la Torre, Hospital Nuestra Señora de Aránzazu (San Sebastián). A. Bustamante, Hospital Marqués de Valdecilla (Santander). R. Bandrés, J.M. Barreiros y J.C. Barros-Tizón, Hospital Xeral de Vigo. J.L. Lobo y M. Pérez, Hospital Txagorritxu (Vitoria). Aguirre y F.J. Suárez-Pinilla, Hospital Clínico (Zaragoza).